PharmAust has announced it will enter phase three of their trial for treatment of pet dogs with B cell lymphoma. This follows the success of phase two in which PharmAust identified the ideal combination of monepantel (MPL, an anthelmintic drug) and prednisolone (a steroid medication) more than doubled the life expectancy of pet dogs compared…